Premium
Severe adverse reactions to Infliximab therapy are common in young children with inflammatory bowel disease
Author(s) -
Kolho KL,
Ruuska T,
Savilahti E
Publication year - 2007
Publication title -
acta pædiatrica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.772
H-Index - 115
eISSN - 1651-2227
pISSN - 0803-5253
DOI - 10.1111/j.1651-2227.2007.00042.x
Subject(s) - medicine , infliximab , adverse effect , azathioprine , disease , inflammatory bowel disease , pediatrics , anaphylaxis , dermatology , allergy , immunology
Since 2000 we have introduced 141 Infliximab infusions to 23 children with severe inflammatory bowel disease. A total of seven severe adverse reactions occurred in 26% (6 of 23) of the children. Four reactions were acute (anaphylaxis n = 2; allergic reaction n = 2) and 3/4 of these children were younger than 10 years of age. Two children developed an abscess and one child had septicaemia and brain lesions related to progressive multifocal leucoencephalopathy. Conclusion: adverse reactions to Infliximab infusions are common. Young children seem to be prone to severe allergic reactions although they are on azathioprine and conventional glucocorticoid therapy.